MD News & Analysis
2 articles
Market Mood
Pediatrix Medical (MD) Stock Downgraded by Jefferies on Valuation
Jefferies has downgraded the stock rating of Pediatrix Medical Group (MD) due to concerns over its valuation. This decision reflects Jefferies' reassessment following market developments and performance metrics. The downgrade could influence market perceptions and investor sentiment towards the company. Investors in Pediatrix Medical should consider how this change may affect their position and the stock's future performance.
Read More: Pediatrix Medical (MD) Stock Downgraded by Jefferies on Valuation
Pediatrix (MD) Reports Q1 EPS Beat with Revenue of $476 Million
Pediatrix Medical Group, Inc. (MD) reported Q1 adjusted EPS of $0.44, surpassing the consensus estimate of $0.38. Revenue for the quarter totaled $476 million, exceeding the expected $465.82 million. Same-unit revenue from net reimbursement-related factors grew 4.4% year over year. The company reaffirmed its FY26 adjusted EBITDA outlook of $280 million to $300 million. Analysts from Jefferies raised their price target on MD to $27 while Truist increased theirs to $23, reflecting confidence in the company's performance amid healthcare service demand trends.
Read More: Pediatrix (MD) Reports Q1 EPS Beat with Revenue of $476 Million